NCT03911973: Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers

Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: BRCA+
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients with TNBC will be assigned to Cohort A, Patients with a HR+ & HER2-negative breast cancer must also have an inherited BRCA 1/2 mutation & will be assigned to Cohort B
Exclusions: Patients with active symptomatic CNS metastatic disease that require treatment- see trial for details

Comments are closed.

Up ↑